Similar articles

Abstract: Differentiated thyroid carcinoma (DTC) generally has a favorable outcome. Thyroid disease, treatments, stress, and comorbidity can compromise health-related quality of life (QoL) and indirectly weigh upon the outcome. From 2004 to 2008, we evaluated QoL longitudinally in 128 DTC subjects. During scheduled examinations, subjects were asked to undergo a semi-structured psychiatric interview and five rated inventories. The same examination was conducted in 219 subjects after surgery for benign thyroid pathology. Low scores represent a better QoL. DTC and control subjects were similar in terms of age, male/female ratio, concomitant psychopharmacological treatments, and frequency of psychiatric diseases. In DTC subjects, Billewicz scale (BS) scores showed an increasing trend over time, especially among females. The ad hoc thyroid questionnaire (TQ) scores were similar in both groups and did not change over time, but at the end of the study ad hoc TQ and BS were significantly related. Ad hoc TQ scores were also related to age on entry to the study. In both male and female DTC subjects, Hamilton’s tests for anxiety (HAM-A), but not for depression (HAM-D), showed an improving trend. At the end of the study, HAM-A and HAM-D scores were comparable to those of the control group. HAM-A and HAM-D were both positively correlated with the stage of cancer and the time between diagnosis and treatment. Only HAM-D correlated with age on entry to the study. Kellner symptom questionnaire (KSQ) item scores were higher in DTC subjects than in controls. The change over time in the items including anxiety, somatization, depression, and hostility was significant. Somatization and hostility were more significantly reduced in DTC females than in DTC males. Hostility scores were significantly lower in DTC subjects than in controls at the end of the study. Somatization and depression were significantly related to staging on diagnosis and age on entry to the study. Our study confirms a wide variation of illness perception in DTC subjects, which is generally unrelated to the favorable clinical follow-up of the disease. psychological evaluation during long-term follow-up improved QoL scores, which reached the same levels noted in subjects with a history of thyroid surgery for benign thyroid pathology. Our data indicate that special attention should be paid to QoL in older DTC subjects and those with more severe staging on diagnosis.

[1]Almeida, J., Vartanian, J.G., Kowalshi, L.P., 2009. Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. Arch. Otolaryngol. Head Neck Surg., 135(4):342-346.

[2]Bianchi, G.P., Zaccheroni, V., Solaroli, E., Viscini, F., Cerutti, R., Zoli, M., Marchesini, G., 2004. Health-related quality of life in patients with thyroid disorders. Qual. Life Res., 13(1):45-54.

[3]Billewicz, W.Z., Chapman, R.S., Crooks, J., Day, M.E., Gossage, J., Wayne, E., Young, J.A., 1969. Statistical methods applied to the diagnosis of hypothyroidism. Q. J. Med., 38(150):255-266.

[4]Biondi, B., Palmieri, E.A., Fazio, S., Cosco, C., Nocera, M., Saccà, L., Filetti, S., Lombardi, G., Perticone, F., 2000. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J. Clin. Endocrinol. Metab., 85(12):4701-4705.

[5]Botella-Carretero, J.I., Galan, J.M., Caballlero, C., Sancho, C., Escobar-Morreale, H.F., 2003. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr. Relat. Cancer, 10(4):601-610.

[6]Crevenna, R., Zettinig, G., Keilani, M., Posch, M., Schmidinger, M., Pirich, C., Nuhr, M., Wolzt, M., Quittan, M., Fialka-Moser, V., et al., 2003. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support. Care Cancer, 11(9):597-603.

[7]Dagan, T., Bedrin, L., Horowitz, Z., Chaushu, G., Wolf, M., Kroenberg, J., Talmi, Y.P., 2004. Quality of life of well-differentiated thyroid carcinoma patients. J. Laryngol. Otol., 118(7):537-542.

[8]Dow, K.H., Ferrell, B.R., Anello, C., 1997. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid, 7(4):613-619.

[9]Fava, G.A., Kellner, R., 1982. Versione Italiana del Symptoms Questionnaire di Kellner. In: Canestrari, R. (Ed.), Nuovi metodi in Psicometria. Organizzazioni Speciali, Firenze, p.51-64 (in Italian).

[10]Giusti, M., Sibilla, F., Cappi, C., Dellepiane, M., Tombesi, F., Ceresola, E., Augeri, C., Rasore, E., Minuto, F., 2005. A case-controlled study of quality of life in a cohort of patients with history of differentiated thyroid carcinoma. J. Endocrinol. Invest., 28(7):599-608.

[11]Golger, A., Fridman, T.R., Eski, S., Witterick, I.J., Freeman, J.L., Walfish, P.G., 2003. Three-week thyroxine withdrawal thyroglobulin stimulating screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J. Endocrinol. Invest., 26(10):1023-1031.

[12]Hamilton, M., 1959. The assessment of anxiety states by rating. Br. J. Med. Psychol., 32(1):50-55.

[13]Hamilton, M., 1960. A rating scale for depression. J. Neurol. Neurosurg. Psychiat., 23(1):56-59.

[14]Hay, I., Bergstralh, E., Goellner, J., Ebersold, J., Grant, C., 1993. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery, 114(6):1050-1058.

[15]Haymart, M.R., 2009. Understanding the relationship between age and thyroid cancer. The Oncologist, 14(3):216-221.

[16]Hirsch, D., Ginat, M., Levy, S., Banbassat, C., Weinstein, R., Tsvetov, G., Singer, J., Shraga-Slutzky, I., Grozinski-Glasberg, S., Mansiterski, Y., et al., 2009. Illness perception in patients with differentiated epithelial cell thyroid cancer. Thyroid, 19(5):459-465.

[17]Hoftijzer, H.C., Heemstra, K.A., Corssmit, E.P., van der Klaauw, A.A., Romijn, J.A., Smit, J.W.A., 2008. Quality of life in cured patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 93(1):200-203.

[18]Jaeschke, R., Guyatt, G., Cook, D., Harper, S., Gerstein, H.C., 1994. Spectrum of quality of life in hypothyroidism. Qual. Life Res., 3(5):323-327.

[19]Kellner, R., 1971. Part 1. Improvement criteria drug trial with neurotic patients. Psychol. Med., 1(5):416-421.

[20]Lee, J., Yun, M.J., Nam, K.H., Choung, W.Y., Soh, E.Y., Park, C.S., 2010. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid, 20(2):173-179.

[21]Ljunggren, J.G., Torring, O., Wallin, G., Taube, A., Tallstedt, L., Hamberger, B., Lundell, G., 1998. Quality of life aspects and costs in treatment of Grave’s hyperthyroidism with anti-thyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid, 8(8):653-659.

[22]Mazzaferri, E.L., Kloss, R.T., 2001. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab., 86(4):1447-1463.

[23]Measso, G., Cavarzeran, F., Zappalà, G., Lebowitz, B.D., Crook, T.H., Pirozzolo, F.J., Amaducci, L.A., Massari, D., Grigoletto, F., 1991. The mini-mental state examination: normative study of an Italian random sample. Dev. Neuropsychol., 9(2):77-85.

[24]Miccoli, P., Minuto, M.N., Saggini, R., Rucci, P., Oppo, A., Donatini, G., Goliam, F., Novelli, L., Carlini, M., Dell′Osso, L., 2007. The impact of thyroidectomy on psychiatric symptoms and quality of life. J. Endocrinol. Invest., 30(10):853-859.

[25]Pacini, F., Castagna, M.G., Cipri, C., Schlumberger, M., 2010. Medullary thyroid carcinoma. Clin. Oncol., 22(6):475-485.

[26]Schlumberger, M.J., Torlontano, M., 2000. Papillary and follicular thyroid carcinoma. Best Pract. Res. Clin. Endocrinol. Metab., 14(4):601-613.

[27]Schroeder, P.R., Haugen, B.R., Pacini, F., Reiners, C.R., Schlumberger, M., Sherman, S.I., Cooper, D.S., Schuff, K.G., Braverman, L.E., Skarulis, M.C., et al., 2006. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J. Clin. Endocrinol. Metab., 91(3):878-884.

[28]Schultz, P.N., Stava, C., Vassiloppoulou-Sellin, R., 2003. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck, 25(5):349-356.

[29]Taïeb, D., Sebag, F., Chrenko, M., Baumstarck-Barrau, K., Fortanier, C., Farman-Ara, B., de Micco, C., Vaillant, J., Thomas, S., Conte-Devolx, B., et al., 2009. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant TSH (rhTSH): a randomized controlled study. Clin. Endocrinol., 71(1):115-123.

[30]Tala, H., Tuttle, R.M., 2010. Contemporary post surgical management of differentiated thyroid carcinoma. Clin. Oncol., 22(6):419-429.

[31]Tan, L.G., Nan, L., Thumboo, J., Sundram, F., Tan, L.K., 2007. Health-related quality of life in thyroid cancer survivors. Laryngoscope, 117(3):507-510.

[32]Terwee, C.B., Dekker, F.W., Mourits, M.P., Gerding, M.N., Baldeschi, L., Kalmann, R., Prummel, M.F., Wiersinga, W.M., 2001. Interpretation and validity of changes in scores on the Grave’s ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin. Endocrinol., 54(3):391-398.

[33]Ware, J.E., Sherbourne, C.D., 1992. The MOS 36-item short-form healthy survey (SF-36). I. Conceptual framework and item selection. Med. Care, 30(6):473-483.

[34]Watt, T., Hegedus, L., Groenvold, M., Bjornerm, J.B., Rasmussen, A.K., Bonemma, S.J., Feldt-Rasmussen, U., 2010. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur. J. Endocrinol., 162(1):161-167.